ImmuCell Co. (NASDAQ:ICCC - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 5,700 shares, a decrease of 51.3% from the May 15th total of 11,700 shares. Based on an average daily volume of 25,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's stock are sold short.
Institutional Investors Weigh In On ImmuCell
Several institutional investors and hedge funds have recently added to or reduced their stakes in ICCC. Geode Capital Management LLC lifted its stake in shares of ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock worth $332,000 after buying an additional 7,878 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its holdings in ImmuCell by 100.0% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 12,178 shares during the period. Northern Trust Corp lifted its position in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Citadel Advisors LLC acquired a new position in ImmuCell during the 4th quarter worth $149,000. Finally, Dauntless Investment Group LLC bought a new stake in ImmuCell during the fourth quarter valued at about $676,000. 13.47% of the stock is currently owned by institutional investors and hedge funds.
ImmuCell Stock Down 0.3%
Shares of ImmuCell stock traded down $0.02 during midday trading on Tuesday, reaching $6.33. 6,185 shares of the company's stock traded hands, compared to its average volume of 22,145. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11. ImmuCell has a 52 week low of $3.34 and a 52 week high of $7.01. The company's 50 day simple moving average is $5.74 and its 200 day simple moving average is $5.28. The company has a market cap of $57.20 million, a price-to-earnings ratio of -12.66 and a beta of 0.30.
ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The company had revenue of $8.07 million for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
